cagrilintide + semaglutide
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
CagriSema is a fixed-dose combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, showing ~22.7% mean weight loss at 68 weeks in the REDEFINE 1 trial. Both components are individually well-characterized, but the combination itself is still investigational and not separately approved. It is heavily searched and sold as either a co-formulated product or paired vials.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published dose for this compound, shown as reference. Included with membership.
